Woburn, MA, September 8, 2017  – Replimune Group Inc. announced today a key addition to its senior leadership team as it progresses its Immulytic™ oncolytic immunotherapy platform rapidly towards clinical trials. Howard L. Kaufman, M.D., FACS has been appointed as the company’s Chief Medical